Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000136 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
A Phase 3 study of Heterozygous Familial Hypercholesterolaemia, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT07000136: Active Phase 3 study of Heterozygous Familial Hypercholesterolaemia, sponsored by AstraZeneca.
NCT07000136 is a Phase 3 study of Heterozygous Familial Hypercholesterolaemia that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 455 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07000136, a Phase 3 study of Heterozygous Familial Hypercholesterolaemia, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will be up to approximately 56 weeks, including a screening period of up to 14 days, treatment with AZD0780 or placebo for 52 weeks, and a safety follow-up period of 10 days.
Primary Outcome
To compare the effect of treatment with AZD0780 versus placebo on LDL-C at 12 weeks
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
Study Locations (20)
Texas
- Research Site - Houston
- Research Site - Humble
- Research Site - Kingwood
- Research Site - McAllen
- Research Site - Mesquite
California
- Research Site - Garden Grove
- Research Site - San Diego
Florida
- Research Site - Hialeah
- Research Site - Orlando
Ohio
- Research Site - Cincinnati
- Research Site - Lima
Georgia
- Research Site - Peachtree Corners
Illinois
- Research Site - Chicago
Louisiana
- Research Site - Hammond
Nevada
- Research Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2025-06-10 |
| Est. Completion | 2027-01-04 |
| Phase | Phase 3 |
What the registry record for NCT07000136 still lists
NCT07000136 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 1 condition, with Heterozygous Familial Hypercholesterolaemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07000136 names 20 study sites across 13 states, led by Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT07000136 about?
NCT07000136 is a clinical study titled "A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH". This is a study to evaluate the efficacy and safety of AZD0780 in adults with HeFH and elevated LDL-C, either with clinical ASCVD and LDL-C levels of 55 mg/dL or higher or without clinical ASCVD and LDL-C levels of 70 mg/dL or higher. AZD0780 is a small molecule that reduces the amount of LDL-C in t...
What is the current status of trial NCT07000136?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 455 participants. The study started on 2025-06-10. Estimated completion is 2027-01-04.
What conditions does trial NCT07000136 study?
This clinical trial studies the following conditions: Heterozygous Familial Hypercholesterolaemia.
What interventions are being tested in trial NCT07000136?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG).
Who is sponsoring clinical trial NCT07000136?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07000136 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07000136's enrollment target sits among peer trials
455 829th of 2000 higher than 1,170 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI